Abstract
Recent studies suggest that obese individuals lose weight more rapidly and lose more
total weight with soy protein than with animal protein as a major diet component.
The purpose of the present study was to evaluate the weight-loss efficacy and changes
in body composition, waist circumference, blood pressure, and levels of plasma glucose,
insulin, serum lipids, C-reactive protein, and homocysteine from consumption of either
3 soy shakes or 3 casein shakes daily as part of a 16-week, energy-restricted diet
for obese women. Forty-three women with body mass index values of 30 to 40 kg/m2 were randomized to intensive dietary interventions using either casein (n = 21) or
soy (n = 22) shakes. Subjects were instructed to consume 3 shakes, 1 prepackaged entrée,
and 5 servings of fruits or vegetables daily to achieve an energy intake of 4.5 to
5.0 MJ/d. Subjects attended classes weekly or biweekly. Weight, body fat, lipid, and
glucose measurements were obtained at baseline and at 8 and 16 weeks. For both groups
combined, subjects lost 8.1% of initial body weight (7.7 kg) at 8 weeks and 13.4%
(12.7 kg) at 16 weeks. Weight loss from baseline did not differ significantly by group
and, for completing subjects, was 14.0% ± 1.2% (mean ± SE) for casein and 12.8% ±
1.4% for soy. With the intention-to-treat analysis, weight losses at 16 weeks were
12.5% ± 1.4% for casein and 11.3% ± 1.2% for soy. Body fat losses were 23.7% ± 2.0%
for casein and 21.8% ± 2.4% for soy and did not differ significantly. Both study groups
lost significant amounts of weight with a highly structured behavioral program incorporating
4 meal replacements and vegetables and fruits. Differences in weight loss and body
composition changes between casein and soy treatments were not significant.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence and trends in obesity among US adults, 1999-2000.JAMA. 2002; 288: 1723-1727
- The worldwide obesity epidemic.Obes Res. 2001; 9: 228S-233S
- The epidemic of obesity.J Clin Endocrinol Metab. 2004; 89: 2522-2525
- Prevalence and trends in overweight among US children and adolescents, 1999-2000.JAMA. 2002; 288: 1728-1732
- Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.JAMA. 2003; 289: 76-79
- Weight loss with self-help compared with a structured commercial program: a randomized trial.JAMA. 2003; 289: 1799-1805
- Structured weight-loss programs: a meta-analysis of weight loss at 24 weeks and assessment of effects of intensity of intervention.Adv Ther. 2004; 21: 61-75
- Long-term weight-loss maintenance: a meta-analysis of US studies.Am J Clin Nutr. 2001; 74: 579-584
- Systematic review: an evaluation of major commercial weight loss programs in the United States.Ann Intern Med. 2005; 142: 56-66
- Meta-analysis: pharmacologic treatment of obesity.Ann Intern Med. 2005; 142: 532-546
- Weight management using a meal replacement strategy: meta and pooling analysis from six studies.Int J Obes. 2003; 27: 537-549
- Weight loss and lipid changes with low-energy diets: comparison of milk-based versus soy-based liquid meal replacement interventions.J Am Coll Nutr. 2005; 24: 210-216
- Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results.Obes Res. 2000; 8: 399-402
- Usual dietary isoflavone intake and body composition in postmenopausal women.Menopause. 2003; 10: 427-432
- Worldwide epidemic of obesity: hope for Japanese diet.Clin Exp Pharmacol Physiol. 2004; 31: S2-S4
- A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial.Eur J Nutr. 2003; 57: 514-522
- Weight loss without losing muscle mass in pre-obese and obese subjects induced by high-soy diet.Int J Obes. 2004; 28: 1349-1352
- Soy isoflavones, body composition, and physical performance.Maturitas. 2006; 52: 102-110
- Soy protein isolate and its hydrolysate reduce body fat of dietary obese rats and genetically obese mice (yellow KK).Nutrition. 2000; 16: 349-354
- A soybean peptide isolate diet promotes postprandial carbohydrate oxidation and energy expenditure in type II diabetic mice.J Nutr. 2003; 133: 752-757
- The soybean B-conglycinin B-51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats.J Nutr. 2003; 133: 2537-2542
- Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats.J Nutr. 2002; 132: 2775-2780
- The soy isoflavone genistein decreases adipose deposition in mice.Endocrinology. 2003; 144: 3315-3320
- Divergent effects of soy protein diet on the expression of adipocytokines.Biochem Biophys Res Commun. 2003; 311: 909-914
- HMR program for weight management weight loss core curriculum.Health Management Resources, Boston (MA)1999
- Insulin secretion and sensitivity in relation to glucose tolerance: lessons from the Botnia Study.Diabetes. 2000; 49: 975-980
- Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial.JAMA. 2006; 295: 1539-1548
- Air displacement plethysmography: validation in overweight and obese subjects.Obes Res. 2005; 13: 1232-1237
- Efficacy of troglitazone on body fat distribution in type 2 diabetes mellitus.Diabetes Care. 2000; 23: 1067-1071
- Adipose tissue quantification by imaging methods: a proposed classification.Obes Res. 2003; 11: 5-16
- Bupropion SR significantly enhances weight loss: a 24-week double-blind, placebo-controlled trial with placebo group randomized to bupropion SR during 24-week extension.Obes Res. 2002; 10: 633-641
- Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.Diabetes Obes Metab. 2002; 4: 270-275
- Obesity and disease management: effects of weight loss on co-morbid conditions.Obes Res. 2001; 9: 326S-334S
Gotthelf L, Anderson JW, O'Brien B: Weight loss in overweight or obese individuals with different structured interventions in an intense behavioral program. Obes Res 12:A402004 (Abstract).
- One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy.J Consult Clin Psychol. 1994; 62: 165-171
- Food provision vs structured meal plans in the behavioral treatment of obesity.Int J Obes. 1996; 20: 56-62
- Results of soy-based meal replacement formula on weight, anthropometry, serum lipids & blood pressure during a 40-week clinical weight loss trial.Nutr J. 2003; 2: 14
- Isoflavone-rich soy protein prevents loss of hip lean mass but does not prevent the shift in regional fat distribution in perimenopausal women.Menopause. 2003; 10: 322-331
- Antihypocholesterolemic effect of undigested fraction of soybean protein in young female volunteers.J Nutr Sci Vitaminol. 1995; 41: 187-195
- Soy protein hydrolyzate with bound phospholipids reduces serum cholesterol levels in hypercholesterolemic adult male volunteers.Biosci Biotechnol Biochem. 2001; 65: 72-78
- Effect of soy and milk whey protein isolates and their hydrolysates on weight reduction in genetically obese mice.Biosci Biotechnol Biochem. 2000; 64: 2594-2600
- Soybean B-conglycinin peptone suppresses food intake and gastric emptying by increasing plasma cholecystokinin levels in rats.J Nutr. 2003; 133: 352-357
- Effects of soybean isoflavones, probiotics, and their interaction on lipid metabolism and endocrine system in an animal model of obesity and diabetes.J Nutr Biochem. 2004; 15: 583-590
- Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin.Biol Pharm Bull. 2001; 24: 368-372
- Effects of isoflavone aglycone in the prevention of obesity in a diet-induced obesity mouse model.Atherosclerosis. 1999; 143: 81-90
- Genistein restricts leptin secretion from rat adipocytes.J Steroid Biochem Mol Biol. 2005; 96: 301-307
Hwang J-T, Park I-J, Shin J-I, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Comm tbd:tbd, 2005.
- Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies.J Am Coll Nutr. 2003; 22: 331-339
- Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes.Diabetes Care. 2002; 25: 1709-1714
- Beneficial role of dietary phytoestrogens in obesity and diabetes.Am J Clin Nutr. 2002; 76: 191-1201
- Soybean β-conglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of β-oxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption.Biosci Biotechnol Biochem. 2004; 68: 352-359
- Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats.J Nutr. 2004; 134: 522-529
- Dietary soybean protein increases insulin receptor gene expression in Wistar fatty rats when dietary polyunsaturated fatty acid level is low.J Nutr. 1997; 127: 1077-1083
- Peroxisome proliferator–activated receptor γ (PPAR γ) as a molecular target for the soy phytoestrogen genistein.J Biol Chem. 2003; 278: 962-967
Article info
Publication history
Accepted:
October 2,
2006
Received:
May 9,
2006
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
